Fletcher D S, Osinga D G, Keenan K, Bonney R J, Doherty J B, Finke P E, Shah S K, Davies P
Merck Research Laboratories, Merck & Co., Rahway, New Jersey, USA.
J Pharmacol Exp Ther. 1995 Jul;274(1):548-54.
The typical reverse passive Arthus reaction (RPA) was attained in rats by the instillation of a rabbit antiovalbumin serum into the lungs and intravenous injection of ovalbumin. Instillation of antiserum alone caused accumulation of polymorphonuclear leukocytes (PMN) and increased vascular permeability, but did not cause hemorrhage. However, when an intravenous injection of ovalbumin was also given, the vascular permeability of the lungs increased dramatically and PMN, as well as hemoglobin, were measurable in the lung lavage fluids by 4 hr after initiation of the reaction. Various proteinase inhibitors were instilled into the lungs after the initial stages of the RPA had developed, specifically to investigate their effect on the development of the hemorrhage, which we chose to monitor as an indicator of severe vascular damage. A cephalosporin-based beta-lactam, L-658,758, which is a time-dependent inhibitor of human and rat PMN elastase, effectively prevented the lung hemorrhage associated with the RPA reaction (ED50 = 2 x 55 micrograms doses/animal when instilled at 1.5 and 2.5 hr after initiating the RPA). The PMN elastase inhibitor, methoxysuccinyl-alanyl-alanyl-prolyl-valine-chloromethylketone, also inhibited hemorrhage in this model. Compounds of the same chemical class as these elastase inhibitors, but having no activity against PMN elastase in vitro, did not affect the hemorrhage associated with the RPA. Several specific inhibitors of proteinases other than PMN elastase (e.g., pepstatin and methoxysuccinyl-prolyl-glycyl-alanyl-lysine-chloromethylketone) were found to have little effect on the hemorrhage associated with the RPA reaction.(ABSTRACT TRUNCATED AT 250 WORDS)
通过向大鼠肺部滴注兔抗卵清蛋白血清并静脉注射卵清蛋白,可引发典型的反向被动阿尔图斯反应(RPA)。单独滴注抗血清会导致多形核白细胞(PMN)积聚并增加血管通透性,但不会引起出血。然而,当同时进行静脉注射卵清蛋白时,肺部血管通透性会急剧增加,并且在反应开始后4小时,肺灌洗液中可检测到PMN以及血红蛋白。在RPA反应初始阶段发展之后,将各种蛋白酶抑制剂滴注到肺部,专门研究它们对出血发展的影响,我们选择将出血作为严重血管损伤的指标进行监测。一种基于头孢菌素的β-内酰胺类药物L-658,758,它是人和大鼠PMN弹性蛋白酶的时间依赖性抑制剂,可有效预防与RPA反应相关的肺出血(在启动RPA后1.5小时和2.5小时滴注时,ED50 = 2×55微克剂量/动物)。PMN弹性蛋白酶抑制剂甲氧基琥珀酰 - 丙氨酰 - 丙氨酰 - 脯氨酰 - 缬氨酸 - 氯甲基酮在该模型中也可抑制出血。与这些弹性蛋白酶抑制剂化学类别相同但在体外对PMN弹性蛋白酶无活性的化合物,不会影响与RPA相关的出血。发现几种除PMN弹性蛋白酶之外的蛋白酶特异性抑制剂(例如胃蛋白酶抑制剂和甲氧基琥珀酰 - 脯氨酰 - 甘氨酰 - 丙氨酰 - 赖氨酸 - 氯甲基酮)对与RPA反应相关的出血几乎没有影响。(摘要截短于250字)